Angelman syndrome-associated epilepsy

An uncommon genetic illness called Angelman syndrome (AS) predominantly affects the nervous system and is caused by many developmental and neurological difficulties. This condition is brought on by the UBE3A (Ubiquitin Protein Ligase E3A) gene losing its ability to function, usually as a result of a mutation or deletion on chromosome 15. A protein that is important in the brain’s neurons’ typical operation is encoded by this gene. Patients with Angelman syndrome frequently show severe speech impairment, developmental delays, and intellectual difficulties. They often exhibit a particular behavioral pattern that includes a propensity for frequent giggles, hyperactivity, and an interest in water. Motor coordination problems are also prevalent, resulting in a particular gait with extending arms. Clinical observations, genetic tests, and molecular methods are frequently used to diagnose this condition early in life. Behavioral and educational support, along with therapeutic therapies including speech and physical therapy, are the main components of the management of Angelman syndrome.

Chromosome 15 abnormalities are the main cause of Angelman syndrome. It can be caused by several genetic factors, such as deletions or mutations in the UBE3A gene, paternal uniparental disomy (getting two copies of chromosome 15 inherited from the father), or imprinting errors. The E3 ubiquitin ligase enzyme, or UBE3A protein, is encoded by the UBE3A gene. This protein is essential for the brain’s neurons to operate normally. It participates in the breakdown of specific proteins, particularly those that control the transmission of synaptic signals and plasticity. An imbalance in the control of synaptic proteins results from the absence of the UBE3A gene. This alteration in synaptic function has the potential to affect neurotransmission, synaptic plasticity, and aberrant neuronal connections in the brain. There is a disruption in the usual silencing of the maternal UBE3A allele in neurons in cases where AS is caused by an imprinting error. This further results in the lack of a functional UBE3A protein in the brain. Research has indicated that GABAergic transmission, which involves neurotransmitters such as gamma-aminobutyric acid, is frequently disturbed in Angelman syndrome. GABA is a neurotransmitter with inhibitory properties that aid in maintaining a healthy balance between neuronal excitement and inhibition in the brain. Seizures and aberrant brain activity seen in Angelman syndrome can be attributed to GABAergic signaling dysregulation.

Our understanding of Angelman syndrome is still expanding, and several therapy options, such as gene therapies and drugs that target particular symptoms, are being investigated. AS emphasizes the complex link between heredity and neurological development by providing insights into more general aspects of neurological and genetic diseases. An important and frequent co-occurring disorder in people with Angelman syndrome is epilepsy. In reality, most people with Angelman syndrome have seizures at some point in their lives. Although the connection between AS and epilepsy is complicated and not entirely understood, there are a few important factors to consider:

1. In Angelman syndrome, seizures often start in infancy and frequently appear within the very first few years of life. Atypical absence seizures, myoclonic seizures, which cause brief, shock-like muscle spasms, and absence seizures of any kind are among the various kinds of seizures that can occur. Generalized tonic-clonic seizures, sometimes referred to as grand mal seizures, are possible once in a while.

2. Angelman Syndrome Seizures can negatively affect an individual’s overall development. They might impair one’s ability to learn, communicate, or move. To achieve the best possible developmental results, seizure control must be effective.

3. Epileptiform discharges, or aberrant electrical brain activity, can be seen in people with Angelman syndrome. Both behavior and cognitive performance may be impacted by these.

The following are some essential elements of the epilepsy treatment strategy for Angelman syndrome:

1. Antiepileptic drugs (ADEs) are the mainstay of treatment for epilepsy. The drug chosen must be adapted over time based on the frequency and kind of seizures. Valproic acid, lamotrigine, levetiracetam, and other AEDs are frequently used. Careful monitoring and modifications may be necessary to determine the best medicine and dosage.

2. It is crucial to regularly track seizure frequency and severity using seizure diaries and/or electroencephalogram (EEG) analyses. These aid medical practitioners in evaluating the efficacy of medications and making the required modifications.

3. An implantable device called vagus nerve stimulation can lessen both the frequency and intensity of seizures. It is considered when medication alone is ineffective at managing seizures.

4. A ketogenic diet, which is a high-fat, low-carbohydrate diet, may be helpful for some people with Angelman syndrome and epilepsy. In situations where medicine has had mixed results, this diet may help lower seizures.

5. Epilepsy may slow down cognitive and developmental growth. Developmental delays and communication difficulties are frequently addressed by integrating behavioral and educational therapies into the treatment plan, including physical therapy, speech therapy, and occupational therapy.

6. Other medical and behavioral conditions, like sleep disorders and hyperactivity, may also affect people with Angelman syndrome and intensify their seizures. Indirectly, seizure control can be improved by treating certain comorbidities.

7. To track development, modify treatment plans, and address any new difficulties, scheduling frequent follow-up visits with a medical team, which should include neurologists and developmental specialists is crucial.

8. Due to the genetic nature of Angelman Syndrome, genetic counseling may be advised for families to better understand the condition’s underlying genetics and to talk about family planning.

Particularly in youngsters, epilepsy can hinder cognitive and developmental growth. Based on variables such as early diagnosis, the success of treatment, and the existence of other neurological diseases, the outcome in terms of cognitive function and development may differ. Epilepsy’s psychosocial effects might affect a person’s quality of life. Relationships, employment, emotional health, and general satisfaction are all included in this. The community’s and healthcare professionals’ support can be extremely important in enhancing psychological results. The general course of epilepsy can be affected by lifestyle variables like reducing stress, adhering to treatment regimens, and avoiding seizure triggers. It might be advised to make lifestyle changes to improve seizure management as well as quality of life.

By: Rubasha Rafiq

References:

Park SH, Yoon JR, Kim HD, Lee JS, Lee YM, Kang HC. Epilepsy in Korean patients with Angelman syndrome. Korean J Pediatr 2012;55:171–6

Meng L, Person RE, Beaudet AL. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. Hum Mol Genet 2012;21:3001–12.

Liljelund P, Ferguson C, Homanics G, Olsen RW. Long-term Effects of Diazepam Treatment of Epileptic GABAA Receptor beta3 Subunit Knockout Mouse in early life. Epilepsy Res 2005;66:99–115.

Judson MC, Wallace ML, Sidorov MS, Burette AC, Gu B, van Woerden GM, et al. GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility. Neuron 2016;90:56–69.

Robinson AA, Goldman S, Barnes G, Goodpaster L, Malow BA. Electroencephalogram (EEG) duration needed to detect abnormalities in Angelman syndrome is 1 hour of overnight recording sufficient? J Child Neurol 2015;30:58–62.

Espay AJ, Andrade DM, Wennberg RA, Lang AE. Atypical absences and recurrent absence status in an adult with Angelman syndrome due to the UBE3A mutation. Epileptic Disord 2005;7:227—30.